An observational study in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-10-31.
Sponsored by Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Glaucoma, Open-Angle with a site in Spain — 6 open to participants now, 9 under way, none of them phase 3. Glaucoma, Open-Angle · Spain.
Among the 47 studies in Glaucoma, Open-Angle with a site in Spain, this one is the 11th largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2021, is one of 12 observational ones, and was the 39th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →6 of the 47 studies in Glaucoma, Open-Angle with a site in Spain are open now. Recruiting first, the newest first:
Santen SAS · Sites in Spain, Austria, Belgium and 5 more countries
Ages 18–85
Institut Catala de Retina · Sites in Spain
Ages 50–75
Elios Vision, Inc. · Sites in Spain, Belgium, France and 3 more countries
Ages 40+
Nova Eye, Inc. · Sites in Spain, Germany, United Kingdom
Ages 22+
iSTAR Medical · Sites in Spain, Panama, United Kingdom
Ages 40+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 5 · Phase 4 9
First in 2002; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Median enrollment 107 across the 35 interventional studies, 198 across the 12 observational. Of the 35 that completed or were terminated, 16 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 47 have an industry lead sponsor. The 10 most frequent:
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA has 1 study filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
4 of the studies in Glaucoma, Open-Angle with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04524416iSTAR MedicalMINIject Global Long-Term Follow-up Study | 2026-12 |
| NCT05786196Nova Eye, Inc.Multicenter Glaucoma Study Investigating Standalone Canaloplasty | 2026-12 |
| NCT07322965Institut Catala de RetinaEvaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma | 2027-04-30 |
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 47 studies in Glaucoma, Open-Angle with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Glaucoma is a chronic optic neuropathy whose main modifiable risk factor is an abnormally elevated intraocular pressure. The aim of glaucoma treatment is to slow the progression of the disease by reducing intraocular pressure.
Prostaglandin derivatives are the most effective topical drugs in reducing intraocular pressure (IOP). Among these, latanoprost was the first agent of this type to be approved for use in patients with glaucoma or ocular hypertension.
These eye drops are available with and without preservatives. There are two commercial brands in our environment, Xalatan®, which contains 0.005% latanoprost and 0.2 mg/ml benzalkonium chloride (BAK) and Monoprost®, which contains the same amount of latanoprost but does not carry a preservative. The prostaglandin analog with a lower concentration of active ingredient available in Spain without preservative is tafluprost 0.0015%, commercially available under the name Saflutan®.
The long-term use of hypotensive eye drops with preservatives generates changes in the ocular surface, such as instability of the tear film, conjunctival inflammation, subconjunctival fibrosis, apoptosis of the conjunctival epithelium and deterioration of the corneal surface, causing symptoms such as stinging, tearing, sensation foreign body, photophobia and blurred vision.
This research will evaluate the changes in the ocular surface and in the expression of inflammatory molecules that occur in the conjunctiva in patients with a diagnosis of glaucoma and ocular hypertension who are under ocular hypotensive treatment with tafluprost, comparing it with the two commercial preparations of latanoprost.
These three groups of patients will have a control group of patients with a diagnosis of ocular hypertension who will not have any topical hypotensive medication.
Adult patients with ocular hypertension or primary open angle glaucoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with primary open angle glaucoma or ocular hypertension treated with Xalatan
Patients with primary open angle glaucoma or ocular hypertension treated with Monoprost
Patients with primary open angle glaucoma or ocular hypertension treated with Saflutan
Patients ocular hypertension untreated
Inflammatory response in ocular surface secondary to prostaglandin use
Presence of inflammatory cytokines in ocular surface
Time frame: 24 hours
Conjunctival cell phenotype and inflammatory infiltration
Conjunctival cell phenotype assessment by conjunctival in vivo confocal microscopy
Time frame: 24 hours
Changes in oxidative stress in the tear film
Changes in oxidative stress at conjunctiva secondary to prostaglandin treatment
Time frame: 24 hours
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2021 (actual). Primary completion is estimated for Dec 2025, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA